Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam Phase 2b in Mild-to-moderate Alzheimer's
NCT04079803Phase 2Completed
- Sponsor
- Cassava Sciences
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of simufilam in Alzheimer's disease (AD), sponsored by Cassava Sciences. Started Sep 2019; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04079803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079803.